Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 2/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 3/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.30 |
| ▸ | KMO | O15229 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL437539 | 0.86 | — | — | |
| SCHEMBL29772482 | 0.86 | — | — | |
| Acetamide SCHEMBL28080052 | 0.75 | PARP1 (0.41) | EGFRCYP1A2 | |
| Quinazoline SCHEMBL27292048 | 0.69 | EGFR (0.71) | EGFRIMPDH2CYP1A2 | |
| SCHEMBL10557945 | 0.68 | PSMD14 (0.45) | NTRK1 | |
| Acetamide SCHEMBL9933180 | 0.68 | NPC1 (0.38) | NTRK1EGFRIMPDH2 | |
| SCHEMBL1101166 | 0.68 | NTRK1 (0.39) | NTRK1CYP1A2 | |
| Acetamide SCHEMBL9934069 | 0.68 | RIPK1 (0.47) | — | |
| Acetamide SCHEMBL9934182 | 0.67 | PIK3C3 (0.38) | NTRK1EGFRIMPDH2 | |
| SCHEMBL16576781 | 0.65 | FTO (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655377-B1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | GLENMARK PHARMACEUTICALS SA (CH) | 2016-03-30 | — | — | EP | disclosed |
| US-9073955-B2 | 2-amino-4-arylthiazole compounds as TRPA1 antagonists | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-8889862-B2 | 2-amino-4-arylthiazole compounds as TRPA1 antagonists | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2014-11-18 | — | — | US | disclosed |
| US-20140051667-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2014-02-20 | — | — | US | disclosed |
| US-20140045865-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2014-02-13 | — | — | US | disclosed |
| US-8592398-B2 | 2-amino-4-arylthiazole compounds as TRPA1 antagonists | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2013-11-26 | — | — | US | disclosed |
| US-20120157411-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157411-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS | TRPA1, TRPV1, TRPV2 | ADORA2B 187/4885NTRK1 798/4885EGFR 1582/4885 |
| US-20140045865-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | ADORA2B 140/4885NTRK1 961/4885EGFR 2050/4885 |
| US-20140051667-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | ADORA2B 140/4885NTRK1 961/4885EGFR 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.